Literature DB >> 22790016

Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in situ in reactive lymphoid tissues.

Patrick Adam1, Ana-Iris Schiefer, Sophie Prill, Tobias Henopp, Leticia Quintanilla-Martínez, Hans-Christian Bösmüller, Andreas Chott, Falko Fend.   

Abstract

Recently, the occurrence of cyclin D1-positive B cells with mantle cell lymphoma phenotype in the inner mantle zones of morphologically inconspicuous lymph nodes has been described and termed mantle cell lymphoma 'in situ'. Prevalence and clinical significance of this lesion and related minimal mantle cell lymphoma infiltrates in reactive lymphoid tissues of healthy individuals, and of mantle cell lymphoma patients are unknown. All 1292 reactive lymph nodes from unselected consecutive surgical specimens of 131 patients without a history of lymphoma obtained over a 3-month period were stained for cyclin D1. In addition, all morphologically reactive lymph nodes and benign-appearing extranodal lymphoid infiltrates of patients diagnosed with mantle cell lymphoma in the years 2000-2011 were studied. Samples predating the lymphoma diagnosis for at least 2 months were available from 37/423 (9%) patients. A mantle cell lymphoma 'in situ' was not identified in any of the two groups. However, in four patients with subsequent mantle cell lymphoma diagnosis, an early manifestation of mantle cell lymphoma was detected retrospectively, antedating the lymphoma diagnosis for 2-86 months. In six mantle cell lymphoma patients, only small groups of cyclin D1-positive cells in morphologically reactive extranodal infiltrates were detected >2 months before the diagnosis of mantle cell lymphoma (range 3-59 months). Mantle cell lymphoma 'in situ' is an extremely rare phenomenon in morphologically reactive lymph nodes, in line with the low prevalence of t(11;14)-positive cells described in the peripheral blood of a healthy population. In mantle cell lymphoma patients, however, immunohistochemically detectable infiltrates of mantle cell lymphoma cells antedating the lymphoma diagnosis were found in a significant proportion of cases (10/37=27%). These consisted either of early mantle cell lymphoma with mantle zone growth pattern, or small extranodal accumulations of cyclin D1+ cells, whereas typical mantle cell lymphoma 'in situ' was not detected.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22790016     DOI: 10.1038/modpathol.2012.117

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

Review 1.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

Review 2.  Early lymphoid lesions: conceptual, diagnostic and clinical challenges.

Authors:  Karthik A Ganapathi; Stefania Pittaluga; Oreofe O Odejide; Arnold S Freedman; Elaine S Jaffe
Journal:  Haematologica       Date:  2014-09       Impact factor: 9.941

3.  Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies.

Authors:  Raju K Pillai; Urvashi Surti; Steven H Swerdlow
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

Review 4.  [In situ lymphoma and other early stage malignant non-Hodgkin lymphomas].

Authors:  L Quintanilla-Martínez; P Adam; F Fend
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

Review 5.  [Classification of malignant lymphomas. Current situation].

Authors:  K Koch; W Klapper
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

6.  Non-Hodgkin's lymphomas, version 4.2014.

Authors:  Andrew D Zelenetz; Leo I Gordon; William G Wierda; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; Nancy Bartlett; John C Byrd; Myron S Czuczman; Luis E Fayad; Richard I Fisher; Martha J Glenn; Nancy Lee Harris; Richard T Hoppe; Steven M Horwitz; Christopher R Kelsey; Youn H Kim; Susan Krivacic; Ann S LaCasce; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Ayman A Saad; Lubomir Sokol; Lode J Swinnen; Christina Tsien; Julie M Vose; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2014-09       Impact factor: 11.908

Review 7.  Mantle cell lymphoma with in situ or mantle zone growth pattern: a study of five cases and review of literature.

Authors:  Peihong Hsu; Tianyu Yang; Silvat Sheikh-Fayyaz; Judith Brody; Jela Bandovic; Sarma Roy; Jordan Laser; Jonathan E Kolitz; Craig Devoe; Xinmin Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

Review 8.  Smoldering mantle cell lymphoma.

Authors:  Haige Ye; Aakash Desai; Dongfeng Zeng; Krystle Nomie; Jorge Romaguera; Makhdum Ahmed; Michael L Wang
Journal:  J Exp Clin Cancer Res       Date:  2017-12-15

Review 9.  The pathologic diagnosis of mantle cell lymphoma.

Authors:  Shaoying Li; Jie Xu; M James You
Journal:  Histol Histopathol       Date:  2021-06-11       Impact factor: 2.303

10.  An overlapping case of in situ mantle cell neoplasia and leukemic non-nodal mantle cell lymphoma.

Authors:  Ryota Matsuoka; Noriaki Sakamoto; Mamiko Sakata-Yanagimoto; Shigeru Chiba; Masayuki Noguchi; Naoya Nakamura
Journal:  J Clin Exp Hematop       Date:  2020-10-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.